News

Angitia Biopharmaceuticals Showcases AGA2115 for Bone Health

Angitia Biopharmaceuticals Showcases AGA2115 for Bone Health

Exciting Developments in Osteogenesis Imperfecta Research

Angitia Biopharmaceuticals has made a significant announcement regarding its ongoing program focused on AGA2115 for the treatment of osteogenesis imperfecta (OI), a rare condition that leads to fragile bones. The company is set to present this data at the esteemed American Society for Bone and Mineral Research (ASBMR) Annual Meeting in 2025.

Oral Presentations Highlighting AGA2115's Potential

The ASBMR has selected several abstracts submitted by Angitia as highlights for the annual meeting. Notably, two of these abstracts will be featured in oral presentations, showcasing the critical role AGA2115 could play in the treatment of OI.

Key Presentation Details

The first oral presentation, titled "AGA2115, a Bispecific Antibody Neutralizing DKK1 and Sclerostin, Increased Bone Formation, Decreased Bone Resorption, and Led to Significant BMD Gains in a First-in-Human Study," will be presented by Dr. Eric Orwoll on September 6, 2025.

The second presentation by Dr. Ann Zovein will focus on findings from studies involving nonhuman primates, emphasizing the impacts of AGA2115 on bone mass and strength.

Poster Presentations Underscoring Broader Impacts

In addition to the oral presentations, Angitia will present three posters about AGA2115's effects on bone health. Collaboration with the Willie Laboratory at the Shriners Hospital for Children further enriches the research presented, indicating a robust commitment to understanding and addressing OI.

Insight into Poster Titles and Presenters

One of the posters, titled "A Bispecific Antibody Targeting Dickkopf-1 and Sclerostin Enhances Bone Mass in Osteogenesis Imperfecta Mouse Models," will be shared by Dr. Michal Kulasek. Dr. Zovein will also co-present another poster exploring AGA2115's efficacy related to bone formation biomarkers.

Understanding Osteogenesis Imperfecta

Osteogenesis imperfecta is characterized by fragile bones due to defective collagen synthesis. It affects approximately 1 in 15,000 live births, often leading to frequent fractures and long-term disabilities in affected patients. The variety of symptoms ranges from mild to life-threatening, highlighting the urgency for effective treatments.

Despite the scale of its impact, there are currently no approved therapies for OI, making Angitia's research even more crucial.

About AGA2115 and Its FDA Designation

AGA2115 stands out as a pioneering bispecific antibody designed specifically to treat OI. It has not only captured the attention of the scientific community but has also received Orphan Drug Designation from the FDA, further attesting to its potential significance. Ongoing studies aim to evaluate the efficacy of AGA2115, with special attention to both adult and pediatric populations.

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is committed to advancing therapeutic options for serious musculoskeletal diseases through innovative research. With a focus on osteoporosis and related conditions, the company continues to leverage scientific expertise to develop impactful treatments, aiming to address significant medical needs in the community.

Contact Information for Inquiries

For more information about Angitia Biopharmaceuticals and its initiatives, interested parties can reach out to William Windham at Solebury Strategic Communications. His contact details are available for those looking to engage further with this promising biotechnology firm.

Frequently Asked Questions

What is AGA2115?

AGA2115 is a bispecific antibody developed by Angitia Biopharmaceuticals for treating osteogenesis imperfecta.

When will the findings be presented?

The findings will be presented at the ASBMR Annual Meeting on September 5-8, 2025.

Why is OI significant to research?

Osteogenesis imperfecta affects thousands and currently has no approved treatments, emphasizing the need for effective solutions.

Who is presenting the findings?

Dr. Eric Orwoll and Dr. Ann Zovein will be prominent figures in presenting the findings associated with AGA2115.

How is Angitia Biopharmaceuticals contributing to this field?

Angitia Biopharmaceuticals is dedicated to developing innovative therapeutics for serious musculoskeletal diseases, including osteoporosis and osteogenesis imperfecta.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 17

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Saban Center Partnership Gives Health Learning a Lift

Updated Category News Views 45

A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 138

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 126

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 164

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
Intel Investors Face January 12 Lead Plaintiff Deadline

Updated Category News Views 110

A Narrow Calendar Window Has Opened Intel holders have another legal deadline to put on the fridge, and this one is not a casual housekeeping item. A securities class action has been filed in the Northern District of California on behalf of investors who bought or acquired Intel shares between July 23, 2026, and October 29, 2026. The deadline to seek appointment as lead...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 81

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 47

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 118

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading

Top 5 Most Recently Viewed Articles

Eastman Chemical’s Stock Surge Marks a Turning Point for Investors

Updated Category News Views 82

Eastman Chemical's Stock Hits New Heights Eastman Chemical Company (NYSE: EMN) has recently reached an impressive milestone, with its stock price climbing to a 52-week high of $107.14. This significant price point reflects growing investor confidence and a positive market outlook for the company. With a remarkable 34.6% increase over the past year, Eastman Chemical has...

Continue Reading
BOS Expands Automation Solutions with New System Orders

Updated Category News Views 270

BOS Secures New Orders for Robotic Solutions BOS Better Online Solutions Ltd. (NASDAQ: BOSC), renowned for its expertise in supply chain technologies, has recently announced a significant milestone. The company secured orders for two innovative robotic packing and palletizing systems aimed at enhancing efficiency in food manufacturing. Details of the New Orders These new...

Continue Reading
Amazon's Cloud and AI Strategy Set to Shape Future Growth

Updated Category News Views 260

Overview Amazon.com, Inc. (NASDAQ: AMZN) plays a crucial role in the realms of e-commerce, cloud computing, digital streaming, and artificial intelligence. Recent analyses from respected financial institutions provide a thorough insight into Amazon's market performance, strategic initiatives, and its future outlook. This article brings together these evaluations, zeroing...

Continue Reading
WTW's Strategic Acquisitions: A Leap into the Future of Insurance

Updated Category News Views 211

WTW Expands Through Innovative Acquisitions Willis Towers Watson Public Ltd., known as WTW, is making headlines with its ambitious strategy to enhance its technology-enabled insurance and workplace benefits services. By announcing two consequential acquisitions, WTW aims to broaden its reach in the middle market while modernizing its client interactions significantly....

Continue Reading
Genmab's Share Buy-Back Program: Recent Transaction Details

Updated Category News Views 173

Introduction to Genmab Genmab A/S is a pioneering biotechnology company based in Copenhagen, Denmark, dedicated to improving the lives of patients through innovative antibody therapies. Founded in 1999, Genmab has continuously worked on developing groundbreaking antibody technology platforms, aiming to advance treatment for serious diseases such as cancer. Share Buy-Back...

Continue Reading